Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lily LL Wong"'
Autor:
Antonio Risitano, Régis Peffault de Latour, Eng Soo Yap, Lily LL Wong, Bor-Sheng Ko, Sung-Soo Yoon, Alexander Roeth, Irina Baltcheva, Julie Milojevic, Niamh Fagan, Kenneth Kulmatycki, Prasanna K Nidamarthy, Guido Junge, Jun Ho Jang
Publikováno v:
Blood. 140:5803-5804
Autor:
Jun Ho Jang, Roberta Demichelis, Larysa Nogaieva, Lily LL Wong, Soo Min Lim, Younsoo Kim, Jihye Park
Publikováno v:
Blood. 140:8658-8659
Autor:
Sui Keat, Ai Sim Goh, Carol Chew Yuen Goh, Hong Siew Tan, Tee Chuan Ong, Sen Mui Tan, Pei Ling Low, Kuldeep Kaur, Ee Leng Gan, See Guan Toh, Tze Shin Leong, Lee Ping Chew, Hock Hin Chua, Lily LL Wong, Gilbert Wilfred, Shan Shan Tan, Christopher Liam, Yang Liang Boo
Publikováno v:
Blood. 140:13232-13233
Autor:
Allison P. Wheeler, Gary Benson, Hermann Eichler, Sidsel Marie Tønder, Katarina Cepo, Victor Jimenez Yuste, Kaan Kavakli, Lily LL Wong, Tadashi Matsushita
Introduction: Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in phase 3 clinical development as a once-daily, subcutaneous prophylaxis across all hemophilia subtypes. The phase 2 trials explorer4 (NCT03196284) and ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f86f6aa9bb63fcec91139163f94f051a
https://hdl.handle.net/11454/77782
https://hdl.handle.net/11454/77782
Autor:
Izabela Rozenberg, Lily Ll Wong, Jun-Ho Jang, Eng Soo Yap, Prasanna Kumar Nidamarthy, Katie Li, Guido Junge, Sung-Soo Yoon, Raghav Chawla, Bor-Sheng Ko
Publikováno v:
Blood. 138:2173-2173
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematological disorder caused by somatic mutations in the phosphatidylinositol glycan A (PIGA) gene in hematopoietic stem cells, resulting in complement alternative pathway (AP
Autor:
Larisa Girshova, Bin Jiang, Shunsuke Izuka, Archrob Khuhapinant, Nahla Hasabou, Takeshi Kadokura, Lily Ll Wong, Elena Martynova, Ramon V. Tiu, Taishi Sakatani, Menghe Yuan, Ligen Liu, Jianda Hu, Jian Li, Jerome Tsen-Chuen Tan, Masato Takeuchi, Xin Du, Sergey N. Bondarenko, Jianxiang Wang, Hao Jiang
Publikováno v:
Blood. 138:695-695
Background: Due to poor prognosis, treatment options for patients with FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML) who are refractory to therapy or have relapsed (R/R) are needed globally. Gilteritinib is approved in multiple countries, incl